US Broker Ratings

Pfizer, Inc. (PFE) Stock Analysis: Exploring a 16% Potential Upside Amid Global Biopharmaceutical Expansion

Pfizer, Inc. (NYSE: PFE), a titan in the healthcare sector, commands significant attention with its expansive portfolio in the drug manufacturing industry. Headquartered in the bustling..

IDEXX Laboratories, Inc. (IDXX) Stock Analysis: Exploring a 7.42% Potential Upside and Robust Revenue Growth

IDEXX Laboratories, Inc. (NASDAQ: IDXX), a leading player in the healthcare sector specializing in diagnostics and research, is capturing investor attention with its impressive market cap..

Labcorp Holdings Inc. (LH) Stock Analysis: Solid Growth and Potential Upside Make It a Compelling Healthcare Play

Labcorp Holdings Inc. (NYSE: LH), a prominent player in the healthcare sector, stands out in the Diagnostics & Research industry with a market capitalization of $23.1..

Alnylam Pharmaceuticals, Inc. (ALNY) Investor Outlook: Navigating Biotech Innovation with Strong Buy Ratings

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) stands at the forefront of the biotechnology sector, garnering significant attention from investors and analysts alike. With a market capitalization of..

Globus Medical, Inc. (GMED) Stock Analysis: Evaluating a 34.72% Potential Upside in the Medical Devices Sector

Globus Medical, Inc. (NYSE: GMED), a titan in the healthcare sector specializing in innovative medical devices, has garnered significant investor interest due to its robust potential..

Masimo Corporation (MASI) Stock Analysis: Exploring a 34% Potential Upside in the Healthcare Sector

Masimo Corporation (MASI), a prominent player in the medical devices industry, is capturing investor attention with a compelling potential upside of 34.26%. As the healthcare sector..

Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis: Navigating a 23.78% Potential Upside with Strong Buy Ratings

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has carved out a significant niche in the biotechnology sector, with a robust portfolio of innovative treatments addressing a wide array..

BioMarin Pharmaceutical Inc. (BMRN) Stock Analysis: Unraveling a 67.52% Potential Upside for Investors

For investors seeking promising opportunities in the biotechnology sector, BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) presents a tantalizing prospect. With a market capitalization of $11.19 billion and..

West Pharmaceutical Services (WST) Investor Outlook: Analyzing the 28.11% Upside Potential

West Pharmaceutical Services, Inc. (NYSE: WST) stands as a stalwart in the healthcare sector, specifically within the Medical Instruments & Supplies industry. As the company approaches..

Royalty Pharma plc (RPRX) Stock Analysis: Exploring a 20% Potential Upside

Royalty Pharma plc (NASDAQ: RPRX) stands as a unique player within the biotechnology industry, specializing as a major buyer of biopharmaceutical royalties and a strategic funder..

Tempus AI, Inc. (TEM) Stock Analysis: Evaluating Growth Potential and Analyst Sentiments

Tempus AI, Inc. (NASDAQ: TEM) is a burgeoning player within the healthcare sector, specializing in health information services. With a market capitalization of $13.18 billion, Tempus..

Medpace Holdings, Inc. (MEDP) Stock Analysis: A Closer Look at Its 89% Return on Equity and Market Performance

Medpace Holdings, Inc. (NASDAQ: MEDP) is a notable player in the healthcare sector, specifically within the diagnostics and research industry. With a market capitalization of $13.36..

Gilead Sciences, Inc. (GILD) Stock Analysis: 10% Upside Potential with Robust Pipeline and Strong Dividend Yield

Gilead Sciences, Inc. (NASDAQ: GILD), a leader in the biopharmaceutical industry, is capturing considerable attention from investors due to its promising upside potential and strong dividend..

Bristol-Myers Squibb (BMY) Stock Analysis: Unlocking a 12.34% Potential Upside in the Healthcare Sector

Bristol-Myers Squibb Company (NYSE: BMY) stands as a cornerstone in the healthcare sector, offering a diverse array of biopharmaceutical products that cater to various therapeutic areas...

AptarGroup, Inc. (ATR) Stock Analysis: Exploring a 23% Upside Potential with Strong Buy Ratings

AptarGroup, Inc. (NYSE: ATR), a leader in the healthcare sector specializing in medical instruments and supplies, is catching the attention of investors due to a promising..

HCA Healthcare, Inc. (HCA) Stock Analysis: Navigating High ROE and Analyst Consensus

HCA Healthcare, Inc. (NYSE: HCA), a stalwart in the medical care facilities sector, operates a vast network of hospitals and related healthcare entities across the United..

The Cooper Companies, Inc. (COO) Stock Analysis: Exploring a 25.83% Potential Upside

The Cooper Companies, Inc. (NYSE: COO), a key player in the healthcare sector, specifically within the medical instruments and supplies industry, is drawing attention from investors..

Koninklijke Philips N.V. (PHG) Stock Analysis: Exploring a Potential 18.81% Upside

Koninklijke Philips N.V. (NYSE: PHG), a prominent player in the healthcare sector, is drawing attention with a potential upside of 18.81% based on the average target..

Dr. Reddy’s Laboratories Ltd (RDY) Stock Analysis: Navigating a 6.93% Potential Upside in a Dynamic Healthcare Market

Dr. Reddy’s Laboratories Ltd (NYSE: RDY) is making waves in the pharmaceutical industry, capturing investor attention with a potential upside of 6.93%. With its operations spanning..

Stryker Corporation (SYK) Stock Analysis: Strong Growth Potential with 10.44% Upside

Stryker Corporation (NYSE: SYK) continues to reinforce its position as a formidable player in the healthcare sector, particularly within the medical devices industry. With a market..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds